What the ALOFT-IPF results mean for Bristol Myers Squibb and pulmonary fibrosis treatment
Bristol Myers Squibb's admilparant meets Phase 3 IPF endpoint at 60 mg, but 120 mg misses. Examine efficacy, safety and FDA prospects.
Pharma & Biotech